Organization
Atsena Therapeutics
2 clinical trials
Clinical trial
A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and Tolerability of ATSN-201 Gene Therapy in Male Subjects With RS1-Associated X-linked RetinoschisisStatus: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 1/2 Dose Escalation Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2DStatus: Active (not recruiting), Estimated PCD: 2023-05-19